{"schema_version":"secwatch.filing_event.v1","accession":"0001872789-24-000016","form_type":"8-K","ticker":"EMBC","cik":"0001872789","company_name":"Embecta Corp.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.039914+00:00","generated_at":"2026-06-02T07:10:39.548615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Embecta Q2 revenue up 3.6% to $287.2M; raises FY2024 guidance above prior range","bullets":["Revenue of $287.2M (+3.6% reported, +4.5% constant currency); U.S. +0.8%, International +6.8%.","Adjusted EPS of $0.67 vs $0.75 prior year; adjusted operating margin of 26.1% vs 30.6%.","Raised FY2024 guidance: revenue $1,111-1,116M (prev. $1,094-1,116M), adj. EPS $2.20-2.30 (prev. $1.95-2.15).","FDA continues review of insulin patch pump 510(k); ERP implementation covers ~85% of revenue.","Declared quarterly dividend of $0.15/share, payable June 14, 2024 to holders of record May 28, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001872789-24-000016","json":"https://secwatch.observer/filing/0001872789-24-000016.json","markdown":"https://secwatch.observer/filing/0001872789-24-000016.md","text":"https://secwatch.observer/filing/0001872789-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1872789/000187278924000016/0001872789-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1872789/000187278924000016/embc-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:10:39.548615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac8997a3d5e2fcca3b4cb7aea605b047db0979e1","claim":"Embecta Corp. reported three and six month periods ended March 31, 2024 results: revenue $287.2 million, net income $28.9 million, EPS $0.50. Guidance raised.","evidence_excerpt":"half of the year, we are raising and tightening our fiscal 2024 outlook for our key financial metrics.\" Second Quarter Fiscal Year 2024 Financial Highlights : • Revenues of $287.2 million, up 3.6% on a reported basis; up 4.5% on a constant currency basis ◦ U.S. revenues increased 0.8% on both a reported and constant currency basis ◦ International revenues","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1872789/000187278924000016/0001872789-24-000016-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six month periods ended March 31, 2024"},{"label":"Revenue","value":"$287.2 million"},{"label":"Net income","value":"$28.9 million"},{"label":"EPS","value":"$0.50"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}